Abstract
Migraine and neuropathic pain are common causes of chronic pain. The exact pathomechanism has not been fully clarified for either disorder, but their pathophysiological backgrounds involve several similar mechanisms. Peripheral sensitization occurs in the neuronal elements of the dorsal root ganglion or the trigeminal ganglion, while central sensitization appears in the second-order neurons in the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. Central neuronal hyperexcitability has been implicated in both disorders, and the emerging evidence suggests alterations in the glutamatergic neurotransmission and N-methyl-D-aspartate-receptor activation. Migraine and neuropathic pain additionally share certain clinical features, such as enhanced sensitivity to sensory stimuli and cutaneous allodynia. The pharmacotherapy of both diseases is often challenging, but several antiepileptic drugs that target hyperexcitability are beneficial for both migraine and neuropathic pain. Kynurenine pathway metabolites are capable of influencing the glutamate receptors, and might therefore be novel candidates for future drug development.
Keywords: Allodynia, glutamate, hyperexcitability, migraine, neuropathic pain, sensitization.
CNS & Neurological Disorders - Drug Targets
Title:Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
Volume: 14 Issue: 5
Author(s): Laszlo Vecsei, Zsofia Majlath, Anna Balog and Janos Tajti
Affiliation:
Keywords: Allodynia, glutamate, hyperexcitability, migraine, neuropathic pain, sensitization.
Abstract: Migraine and neuropathic pain are common causes of chronic pain. The exact pathomechanism has not been fully clarified for either disorder, but their pathophysiological backgrounds involve several similar mechanisms. Peripheral sensitization occurs in the neuronal elements of the dorsal root ganglion or the trigeminal ganglion, while central sensitization appears in the second-order neurons in the dorsal horn of the spinal cord or the trigeminal nucleus caudalis. Central neuronal hyperexcitability has been implicated in both disorders, and the emerging evidence suggests alterations in the glutamatergic neurotransmission and N-methyl-D-aspartate-receptor activation. Migraine and neuropathic pain additionally share certain clinical features, such as enhanced sensitivity to sensory stimuli and cutaneous allodynia. The pharmacotherapy of both diseases is often challenging, but several antiepileptic drugs that target hyperexcitability are beneficial for both migraine and neuropathic pain. Kynurenine pathway metabolites are capable of influencing the glutamate receptors, and might therefore be novel candidates for future drug development.
Export Options
About this article
Cite this article as:
Vecsei Laszlo, Majlath Zsofia, Balog Anna and Tajti Janos, Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability, CNS & Neurological Disorders - Drug Targets 2015; 14 (5) . https://dx.doi.org/10.2174/1871527314666150429114040
DOI https://dx.doi.org/10.2174/1871527314666150429114040 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Evaluation of Specific Antibody Responses in Patients with Selective IgA Deficiency and Ataxia Telangiectasia
Endocrine, Metabolic & Immune Disorders - Drug Targets Strategies for Strengthening Patent Protection of Pharmaceutical Inventions in Light of Federal Court Decisions
Current Topics in Medicinal Chemistry The Role of Newer Antiglutamatergic Agents as Mood-Stabilizers in Bipolar Disorder
Current Drug Targets Postnatal Repeated Mild Stress and DEγE Treatment Induce a Reduction of S of DBA/2J in Mice
Letters in Drug Design & Discovery Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Halogenated Derivatives of Aromatic Amino Acids Exhibit Balanced Antiglutamatergic Actions: Potential Applications for the Treatment of Neurological and Neuropsychiatric Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Renin-Angiotensin System in Central Nervous System Diseases and its Interaction with COVID-19
Current Medicinal Chemistry Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Teratogenic Activity of HDAC Inhibitors
Current Pharmaceutical Design EEG Correlates of Cognitive Functions and Neuropsychiatric Disorders: A Review of Oscillatory Activity and Neural Synchrony Abnormalities
Current Psychiatry Research and Reviews Clinical Neurophysiology of Brain Plasticity in Aging Brain
Current Pharmaceutical Design Interaction of Different Proteins with GABA<sub>A</sub> Receptor and their Modulatory Effect on Inhibitory Neural Transmission Leads to Epilepsy
CNS & Neurological Disorders - Drug Targets Cofactors and Metabolites as Protein Folding Helpers in Metabolic Diseases
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Mental Diseases in Medicinal Chemistry: From Synthetic and Natural Drugs to their Therapeutic Treatments)
Current Topics in Medicinal Chemistry Navigating the Sea Changes in Patent Law to Successfully Build Value
Technology Transfer and Entrepreneurship (Discontinued) Role of Natural Plant Products Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry The Effects of Locus Coeruleus and Norepinephrine in Methamphetamine Toxicity
Current Neuropharmacology Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening